Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma
10.3969/j.issn.1001-5256.2023.07.033
- VernacularTitle:不可切除肝细胞癌的经肝动脉化疗栓塞术联合靶向药物或程序性死亡受体1及其配体单抗治疗进展
- Author:
Qiuju PENG
1
;
Tao DAI
1
;
Guibo XIE
1
;
Jinjun CHEN
2
;
Xiao CHENG
2
;
Yuan YAN
1
Author Information
1. Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2. Department of Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
- Publication Type:Review
- Keywords:
Carcinoma, Hepatocellular;
Chemoembolization, Therapeutic;
Molecular Targeted Therapy;
Immune Checkpoint Inhibitors;
Drug Therapy, Combination
- From:
Journal of Clinical Hepatology
2023;39(7):1740-1746
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter arterial chemoembolization (TACE) is recommended by domestic and international guidelines for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), and it is one of the most common treatment methods for patients with uHCC. The chemotherapy drugs commonly used in TACE for HCC include epirubicin, cisplatin, and fluorouracil, while it is still unclear which chemotherapy drug has a better clinical effect. This article summarizes the studies of different TACE regimens using different chemotherapy drugs in the treatment of patients with uHCC in the recent five years. TACE combined with sorafenib can significantly improve the survival of patients with advanced HCC and has been recommended for the treatment of such patients by Chinese Society of Clinical Oncology guidelines, and the efficacy of TACE combined with other tyrosine kinase inhibitors (TKI) has become a research hotspot. Studies have shown that compared with TACE combined with sorafenib in the treatment of patients with advanced HCC, TACE combined with lenvatinib can achieve a significantly longer progression-free survival time and a tendency of increase in median overall survival time. However, due to the variation of target receptors or downstream signals, resistance to molecular-targeted agents is still a challenging problem. TKI combined with immune checkpoint inhibitors may be a promising strategy for the treatment of patients with uHCC. Some studies suggest that triple therapy using TACE combined with TKIs and anti-PD-1/PD-L1 monoclonal antibody has better efficacy in improving the survival of patients with uHCC. This article reviews the studies of the efficacy and safety of TACE combined with targeted agents and TACE combined with anti-PD-1/PD-L1 monoclonal antibody in the treatment of patients with uHCC in the recent five years.
